Royalty Pharma plc Class A Ordinary Shares · XNAS · 131 sessions on record
$58.36▲ +0.14 · +0.2%from $58.22 the session before · Sep 30, 2026 close · end of day
Open
$58.07
High
$58.64
Low
$57.70
Day's range
$0.941.6% of the previous close
VWAP
$58.40close −0.07% from it
Volume, shares
3.65M1.12× the 20-session average
Traded, $
$213.4M
Trades
36K100 shares per trade
Previous close
$58.22+0.14 to the close
Market cap
$22.65Bat the close of Sep 30
Day range70% of the way up
$57.70$58.64
52-week range68% of the way up
$45.79 Mar 25$64.38 Sep 4
−9.4% from the high · +27% from the low
Options
No listed options on RPRX
Close $ · S&P 500 rebased to the first close126 sessions to Sep 30 · axis fixed at 4 × ATR-14 around the last close · hover or tap a session and the read beside the chart follows it
consolidated · latest filed Aug 5, 2026 · SEC filings
Revenue $674.1M, +17% on a year earlier; profit $17.9M, −44% in the Jun 2026 quarter, consolidated.
Last 8 quarters, consolidatedUS dollars as filed · year on year against the same quarter a year earlier · market: close on the first session after the filing against the last close before it, S&P 500 over the same session
Quarterly results of RPRX on the consolidated basis with the market's move on the first session after each filing
Quarter
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
Market on the day
Jun 2026filed Aug 5
$674.1M
▲ +17%
$17.9M
▼ −44%
0.04
▼ −0.8%S&P 500 −0.2% · −0.7 pp
Mar 2026filed May 6
$630.6M
▲ +11%
$294.7M
▲ +23%
0.67
▼ −1.0%S&P 500 −0.3% · −0.7 pp
Dec 2025filed Feb 11
$622.0M
▲ +4.8%
$211.2M
▲ +1.4%
0.49
—not reached
Sep 2025filed Nov 5
$609.3M
▲ +7.9%
$288.2M
▼ −47%
0.67
—not reached
Jun 2025filed Aug 5
$578.7M
▲ +7.7%
$32.2M
▼ −68%
0.07
▼ −0.8%S&P 500 −0.2% · −0.7 pp
Mar 2025filed May 6
$568.2M
▲ +0.05%
$239.3M
▲ +4,900%
0.55
▼ −1.0%S&P 500 −0.3% · −0.7 pp
Dec 2024filed Feb 12
$593.6M
▼ −0.41%
$208.2M
▼ −58%
0.46
—not reached
Sep 2024filed Nov 5
$564.7M
▲ +5.3%
$544.0M
▲ +650%
1.21
—not reached
By fiscal yearfiscal years as filed in the 10-K · named by the year the fiscal year ends
Financial-year results of RPRX on the consolidated basis, summed from the quarters filed
Year
Revenue $
Revenue YoY
Profit $
Profit YoY
EPS $
FY25to Dec 2025
$2.38B
▲ +5.1%
$770.9M
▼ −10%
1.78
FY24to Dec 2024
$2.26B
▼ −3.9%
$859.0M
▼ −24%
1.91
FY23to Dec 2023
$2.35B
▲ +5.2%
$1.13B
▲ +2,500%
2.53
FY22to Dec 2022
$2.24B
▼ −2.3%
$42.8M
▼ −93%
0.10
FY21to Dec 2021
$2.29B
▲ +7.9%
$619.7M
▼ −36%
1.49
Fundamentals
consolidated · filings to Jun 2026 · close $58.36 on Sep 30
RPRX trades at 31 times trailing earnings against 20 for its industry, revenue +10% over twelve months, a 0.81% dividend yield, market cap $22.65B.
Valuation
Market cap
$22.65Bon Sep 30
Price to earnings
31consolidated · four quarters to Jun 2026 · industry 20
Trailing EPS
$1.87diluted · consolidated · four quarters to Jun 2026
Price to book
—
Book value a share
—
Debt to equity
—
Return on equity
—
Dividend yield
0.81%$0.47 a share in 365 days
Price to sales
8.9market cap over revenue, four quarters to Jun 2026
Shares outstanding
388Mon Sep 30
Growthsums of the four quarters filed to Jun 2026 · growth against the four quarters before them · consolidated
Revenue, trailing 12 months
$2.54Bfour quarters to Jun 2026
Revenue growth, 12 months
▲ +10%against the twelve months before
Revenue 3-year CAGR
▲ +2.4%trailing twelve months against the twelve months 3 years earlier · consolidated
Profit, trailing 12 months
$812.0Mfour quarters to Jun 2026
Profit growth, 12 months
▼ −21%against the twelve months before
Profit 3-year CAGR
▲ +47%trailing twelve months against the twelve months 3 years earlier · consolidated
PeersPharmaceutical Preparations · the ten largest by market cap · industry P/E 20, market caps over trailing profit of 6 stocks
Stocks in the industry Pharmaceutical Preparations with market cap, price to earnings and price to book
Pharmaceutical Preparations · SEC standard industrial classification
SEC CIK
1802768
Sessions on record
131
Price source
End of day · delayed
Computed
1 Oct, 10:41 pm IST
OI Charts is not a registered investment adviser or broker-dealer. Prices, filings and open interest are public data and arithmetic on it, not a basis for any investment decision.